BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model

Noetik announced a five-year strategic collaboration and AI model licensing agreement with GSK. The partnership provides GSK’s AI and Therapeutics teams with a direct, non-exclusive license to access Noetik’s OCTO-VC virtual cell foundation models in non-small cell lung cancer and colorectal cancer. The collaboration combines GSK’s leadership in AI and tumor immunology with Noetik’s industry-first virtual cell simulation technology to accelerate the development of novel medicines. Additionally, the companies will collaborate to generate bespoke human spatial datasets, applying human-first biological simulation to areas of strategic interest. Press release. 

Bayer and Cradle have entered a three-year strategic collaboration to deploy Cradle's scientific AI software platform for protein engineering. As part of the collaboration, Bayer will integrate the generative AI platform into existing R&D workflows to enhance lead generation and optimization across its therapeutic antibody pipeline. Bayer selected Cradle's platform to bring higher-quality molecules into clinical development faster by reducing the number of optimization cycles, improving molecular potency, safety and manufacturability, and increasing probability of technical success as Bayer expands to more demanding modes of action. Press release. 

BigHat Biosciences announced a collaboration with Eli Lilly and Company focused on advancing machine-learning-enabled biologics discovery through Lilly TuneLab. This project expands BigHat’s relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody therapeutics. Press release. 

Revvity is another company that has entered a collaboration with Lilly that makes Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals Xynthetica offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery. Through Revvity’s Models-as‑a‑Service framework and its Signals Xynthetica offering, participating organizations will be able to apply Lilly’s predictive models to their own discovery programs while keeping proprietary data private and secure. This approach amplifies the value of contributions from small and midsized‑biotechs, whose diverse experimental data can significantly enhance collective predictive performance. Press release. 

The American Society of Gene & Cell Therapy and the Orphan Therapeutics Accelerator announced a partnership to establish CGTxchange, a jointly owned entity that will serve as a clearinghouse and marketplace for deprioritized cell and gene therapies (CGTs). The new joint venture will address a growing and urgent challenge facing the CGT field: policy and economic shifts in recent years have led biopharma sponsors to halt development of hundreds of CGTs no longer considered commercially viable by traditional industry standards, including many that delivered clear benefits to patients in trials. Press release. 

AAX Biotech and Vascurie announced a new collaboration in the field of neuro-oncology. The collaboration will use AAX’s Seqitope platform and automation infrastructure to speed up the characterization of therapeutic antibodies. AAX will use Seqitope, which has the capacity for high-throughput epitope mapping, to characterize Vascurie’s established antibody candidates against CD93, a new neuro-oncology drug target. Seqitope integrates both amino acid-level epitope insights and the capability to process a significant number of antibodies simultaneously, which aids and accelerates the development of new therapies. Press release. 

Immunai has signed an agreement with Bristol Myers Squibb to support the pharmaceutical group’s clinical development efforts through advanced immune-data analysis. Under the agreement, Immunai will apply its AI-powered operating system, AMICA-OS, to analyze high-dimensional immune data generated in Bristol Myers Squibb’s clinical studies. The work is intended to help deepen understanding of patient immune responses and variability in treatment outcomes, with the aim of informing clinical decision-making during drug development. Press release. 

SandboxAQ launched AQAffinity, a new AI model designed to unblock one of the most persistent bottlenecks in drug discovery: the need for experimentally determined structures. Built on top of the OpenFold Consortium's OpenFold3 biomolecular co-folding model, AQAffinity enables rapid, structure-free drug affinity prediction. AQAffinity allows researchers to "fail fast" on low-probability paths and double down on promising candidates earlier. This capability is critical for de-risking challenging targets, such as less structurally characterized proteins, effectively improving the odds of clinical success before wet lab cycles even begin. Press release. 

Singer Instruments has released a microbial colony picker technology that sets a new standard for speed and repeatability. It has been achieved through the integration of AI technologies. Previous versions of this colony picking technology have already saved a total of more than 38 years of scientists’ time since its original inception back in 2017. Now, with a verified picking speed of 3,000+ colonies per hour at 99.8% accuracy, it is set to enable even more major advances in phage therapy, cancer research, climate change, and antimicrobial resistance, to name just a few. Press release. 

Guard Therapeutics announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research Alliance (ERDERA), aimed at accelerating the development of therapies for rare kidney diseases. The project, titled “A pre-clinical target validation and therapy studies pipeline for treating human Alport spectrum disease” (ALP-RARE), aims to accelerate the development of novel, disease-modifying therapies for Alport syndrome, a group of rare genetic kidney diseases with no approved treatments targeting the underlying cause. Press release. 

Decoy Therapeutics announced the development of a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals is a key “funded development” of Decoy's Global Access Commitment Agreement with the Gates Foundation. Decoy is creating an easily transferable manufacturing capability for peptide-conjugate antiviral fusion inhibitors designed on its IMP3ACT platform that can rapidly advance therapeutic products from laboratory to commercial scale. This manufacturing capability will be designed to enable cost-efficient, rapid, and repeatable scale-up on standard commercial peptide-synthesis machinery, thus enabling a network of global manufacturing facilities that can be flexibly configured to meet demand. Press release. 

Amphastar Pharmaceuticals has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co. for the development, and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs (also termed corticotropin), now designated AMP-110, in the United States and Canada. AMP-110 is designed to address inflammatory and autoimmune conditions with a potentially improved safety profile compared to porcine-derived ACTH products. Press release. 

Evotec SE announced that its Seattle-based subsidiary, Just - Evotec Biologics has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design suite of computational technologies called J.MD. Under the grant terms, Just - Evotec Biologics will leverage its J.MD Molecular Design service that integrates advanced computational tools and high-throughput methodologies to streamline the biologics development process. By optimizing molecular design from the earliest stages, J.MD ensures manufacturability, stability, and efficacy-critical factors for reducing costs and enabling expansion of global access to these therapies, as well as limiting liabilities such as immunogenicity and instability. The new investment will enable 10 new J.MD projects over the next three years, spanning the development of biotherapeutics targeting multiple global health disease indications of concern. Press release. 

Somite announced its new identity, Cellular Intelligence. This rebrand reflects the company's vision to understand, predict, and control cell behavior. To mark the launch, the company released a white paper, Engineering Cell Fate: Towards a Foundation Model for Virtual Cell Signaling, detailing its approach to achieving that vision. The white paper outlines Cellular Intelligence's solution to the challenge of predicting and controlling cellular behavior with the development of the first universal virtual cell-signaling model. It details how, in less than two years, the company progressed from concept to demonstrating in vitro and in silico proof-of-concept results. The white paper also outlines the company's roadmap for the future, and highlights the applications and impact on the field, and ultimately on patient lives. Press release. 

Unchained Labs just launched a brand-new application on Stunner that delivers rapid, low-volume antibody-drug conjugate (ADC) characterization on up to 96 samples at a time. ADCs are complicated, and pinning down what is made is difficult, especially early in development when sample details are scarce and the process is still in flux. Stunner helps with the tedious parts of the ADC screening process. It cleanly separates antibody and drug contributions, untangling the overlapping signals that confuse standard UV/Vis methods while eliminating the long wait times of serial, one-by-one measurements. By teaming up UV/Vis and dynamic light scattering, Stunner helps researchers with faster conjugation comparisons, check consistency across process steps, and make better decisions earlier in development. Press release.